ストックスクリーナーアプリを入手
17.38
0.69%
-0.12
アフターアワーズ：
17.35
-0.03
-0.17%
前日終値:
$17.50
開ける：
$17.55
24時間の取引高:
1.03M
Relative Volume:
0.93
時価総額：
$1.80B
収益：
$71.78M
当期純損益:
$-295.28M
株価収益率:
-5.5005
EPS:
-3.1597
ネットキャッシュフロー:
$-271.85M
1週間 パフォーマンス:
+14.04%
1か月 パフォーマンス:
+4.20%
6か月 パフォーマンス:
+1.05%
1年 パフォーマンス:
+78.81%
1日の値動き範囲:
$17.08
$17.82
1週間の範囲:
$15.32
$17.85
52週間の値動き範囲:
$8.195
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
名前
Nurix Therapeutics Inc
セクター
電話
(415) 660-5320
住所
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
17.38 | 1.81B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-03-17 | 開始されました | Leerink Partners | Market Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-11 | 開始されました | Jefferies | Buy |
| 2024-09-06 | 再開されました | Robert W. Baird | Outperform |
| 2024-07-31 | 開始されました | Truist | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-09 | 開始されました | Barclays | Overweight |
| 2023-02-28 | 開始されました | Oppenheimer | Outperform |
| 2022-10-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-12-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-30 | 再開されました | Piper Sandler | Overweight |
| 2021-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-11-19 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | Stifel | Buy |
すべてを表示
Nurix Therapeutics Inc (NRIX) 最新ニュース
Price-Driven Insight from (NRIX) for Rule-Based Strategy - Stock Traders Daily
Nurix Therapeutics stock (US67079U1007): clinical pipeline and market reaction under the microscope - AD HOC NEWS
Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
NRIX Reiterated by BTIG -- Price Target Maintained at $30 - GuruFocus
Nurix Therapeutics (NRIX) moves 6.9% higher: Will this strength last? - MSN
A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection - simplywall.st
Which Is a Better Investment, Kymera Therapeutics, Inc. or Nurix Therapeutics, Inc. Stock? - AAII
Nurix Therapeutics' (NRIX) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Nurix Therapeutics : NRIX - 24/7 Wall St.
Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG - Moomoo
Nurix Therapeutics (NRIX) director awarded 31,250 stock options at $15.86 strike - Stock Titan
Nurix (NRIX) director granted stock options on 31,250 common shares - Stock Titan
Nurix Therapeutics (NRIX) director receives 31,250-share stock option grant - Stock Titan
Nurix Therapeutics (NRIX) director receives grant of 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director granted 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director gets 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director awarded 31,250 stock options - Stock Titan
Nurix Therapeutics Shareholders Back Directors and Governance Proposals - TipRanks
Vestal Point (NRIX) discloses 6.5M-share stake, 6.3% of float - Stock Titan
Nurix Therapeutics (NRIX) shareholders approve directors, PwC audit and say-on-pay - Stock Titan
Nurix Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Stifel Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Deep Track files 6.17% ownership in Nurix Therapeutics (NRIX) — 6.35M shares - Stock Titan
Nurix Therapeutics presents fresh preclinical and early clinical results for NX-5948 in CSU - Traders Union
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting - Investing News Network
Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative? - simplywall.st
Experimental hives pill from Nurix shows 25x lab potency vs remibrutinib - Stock Titan
(NRIX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Nurix Therapeutics stock (US67079U1007): Analysts see 144% upside potential - AD HOC NEWS
Nurix Therapeutics, Inc.Common stock (NQ: NRIX - FinancialContent
Nurix stock delivers 64% return after Fair Value identified opportunity By Investing.com - Investing.com Australia
Is Nurix Therapeutics (NRIX) Stock’s Premium P/S Multiple Fair After Recent Mixed Share Price Performance - Yahoo Finance
Nurix stock delivers 64% return after Fair Value identified opportunity - Investing.com
How Investors Are Reacting To Nurix Therapeutics (NRIX) Securing EHA Oral Slot For BTK Degrader Data - Yahoo Finance
Nurix Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Oppenheimer Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Vanguard Group Inc. Purchases 1,460,736 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix CEO to speak at two May–June healthcare investor events - Stock Titan
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress - The Manila Times
Nurix Therapeutics Announces Bexobrutideg Oral Presentation - TradingView
Nurix Therapeutics to present new Phase 1a b data on BTK degrader NX-5948 in CLL at EHA2026 - Traders Union
TradingKey - TradingKey
A Look At Nurix Therapeutics (NRIX) Valuation After Recent Share Price Move - Sahm
Nurix Therapeutics stock (US67079U1007): Biotech firm trading with deep losses and cash cushion - AD HOC NEWS
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 - Yahoo Finance
Number of shareholders of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
FMR LLC Boosts Position in Nurix (NRIX) — 5.54M Shares Reported - Stock Titan
Nurix CFO Hans van Houte sells $233k in company stock - Investing.com Canada
Houte Hans Van Sells 14,055 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics (NRIX) CFO sells 14,055 shares in planned trade - Stock Titan
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Nurix Therapeutics Inc (NRIX) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):